Abbisko Therapeutics Reports Positive Phase 2 Lavengratinib Data
Shanghai, China, September 21, 2026 Abbisko Therapeutics has announced positive preliminary results from a Phase 2 clinical study evaluating...
FGFR3
Advertisement
Insilico Doses First Patient in AI-Driven Phase 3 IPF Trial
New York, New York, September 10, 2026 Insilico Medicine has announced that the first patient has been dosed in...
IDEAYA and Servier Launch Phase 3 Uveal Melanoma Trial
South San Francisco, California and Paris, France, September 9, 2026 IDEAYA Biosciences and Servier have announced that the first...
Tyra Reports Phase 2 Dabogratinib Results in Bladder Cancer
San Diego, California, September 10, 2026 Tyra Biosciences, Inc. has reported initial results from the Phase 2 SURF302 clinical...
BridgeBio Advances Oral Infigratinib Toward Achondroplasia Launch
PALO ALTO, Calif. — September 9, 2026 BridgeBio Pharma, Inc. presented new exploratory analyses from the Phase 3 PROPEL...
Advertisements
Tyra to Present Dabogratinib Phase 2 Bladder Cancer Data
Carlsbad, California, USA, September 4, 2026 Tyra Biosciences, Inc. has announced that it will host a conference call and...
AstraZeneca Tagrisso Combo Improves Lung Cancer PFS
Cambridge, UK, September 1, 2026 AstraZeneca has announced positive high-level results from the Phase III SANOVO trial, showing that...
Ascendis, BioMarin Reach Global YUVIWEL License Deal
COPENHAGEN, Denmark, August 31, 2026 Ascendis Pharma A/S and BioMarin Pharmaceutical Inc. have entered into a binding term sheet...
BioMarin FDA Accepts VOXZOGO sNDA for Full Approval
SAN RAFAEL, Calif., July 13, 2026 BioMarin Pharmaceutical Inc. has reached a significant regulatory milestone after the U.S. Food...
BridgeBio Reports Positive Phase 3 Oral Infigratinib Results for Achondroplasia
PALO ALTO, Calif., June 28, 2026 BridgeBio Pharma announced that positive results from its pivotal Phase 3 PROPEL 3...
Advertisement
